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Abstract
Overexpressed cell-surface receptors are hallmarks of many disease states and are often used as 
markers for targeting diseased cells over healthy counterparts. Cell adhesion peptides, which are 
often derived from interacting regions of these receptor-ligand proteins, mimic surfaces of intact 
proteins and, thus, have been studied as targeting agents for various payloads to certain cell targets 
for cancers and autoimmune diseases. Because many cytotoxic agents in the free form are often 
harmful to healthy cells, the use of cell adhesion peptides in targeting their delivery to diseased 
cells has been studied to potentially reduce required effective doses and associated harmful side-
effects. In this review, multiple cell adhesion peptides from extracellular matrix and ICAM 
proteins were used to selectively direct drug payloads, signal-inhibitor peptides, and diagnostic 
molecules, to diseased cells over normal counterparts. RGD constructs have been used to improve 
the selectivity and efficacy of diagnostic and drug-peptide conjugates against cancer cells. From 
this precedent, novel conjugates of antigenic and cell adhesion peptides, called bifunctional 
peptide inhibitors (BPIs), have been designed to selectively regulate immune cells and suppress 
harmful inflammatory responses in autoimmune diseases. Similar peptide conjugations with 
imaging agents have delivered promising diagnostic methods in animal models of rheumatoid 
arthritis. BPIs have also been shown to generate immune tolerance and suppress autoimmune 
diseases in animal models of type-1 diabetes, rheumatoid arthritis, and multiple sclerosis. 
Collectively, these studies show the potential of cell adhesion peptides in improving the delivery of 
drugs and diagnostic agents to diseased cells in clinical settings.
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A. Cell Adhesion Molecules and Their Roles in Biology
Cells interact with their surroundings in different ways to fulfill various functions, ranging 
from vital intercellular signaling to the formation of an intercellular junction of biological 
barriers (i.e., intestinal mucosa barrier and blood-brain barrier [BBB]). Cell adhesion 
proteins play important roles in various diseases including, tumor metastasis, angiogenesis, 
tumor invasion, inflammation, thrombosis, and autoimmune diseases (i.e., Type-1 diabetes 
(T1D), multiple sclerosis (MS), rheumatoid arthritis (RA), Crohn’s) [1–4]. The changes in 
the expression of cell adhesion proteins on the cell surface can be used as biomarkers for a 
HHS Public Access
Author manuscript
Curr Top Med Chem. Author manuscript; available in PMC 2018 March 04.
Published in final edited form as:













disease state as well as for distinguishing diseased cells from normal ones. For example, the 
upregulation of cell adhesion receptors, αVβ3 and αVβ5 integrins, has been shown during 
angiogenesis in tumors [5]. Thus, cell adhesion proteins have been used as targets for (a) 
development of diagnostic agents, (b) drug development by inhibiting cell-adhesion process 
and signaling, and (c) directing drug molecules specifically to disease cells with upregulated 
cell adhesion proteins [3–4, 6–11].
Cell adhesion molecules (CAMs) are glycoproteins found on the cell surface and 
extracellular matrices (ECM) and are involved in homophilic and heterophilic protein-
protein interactions during the cell adhesion process [12–13]. Homophilic interactions 
involve interactions between two of the same proteins, while heterophilic interactions are 
mediated by two different cell adhesion molecules. CAMs are responsible for (a) anchoring 
cells in tissues, (b) cell migrations, (c) cell-cell communications (signaling), and (d) 
connecting cells in the intercellular junctions of biological barriers (i.e., intestinal mucosa 
and the BBB). There are several families of cell adhesion molecules, including (a) integrin 
receptors, (b) immunoglobulins, (c) cadherins, (d) selectins, and (e) extracellular matrix 
proteins [13–17]. The integrin family is a combination of various heterodimers of α- and β-
subunits on the cell surface. Several members of the integrin family include fibronectin 
receptor (FNR), vitronectin receptor (VNR), very late antigen-4 (VLA-4), and lymphocyte 
function-associated antigen-1 (LFA-1). The integrin family has cell-signaling roles during 
cell migration as well as immune cell activation, including their involvement in the “outside-
in” and “inside-out” signaling processes in immune cell activation and the cell adhesion 
process.
The members of the immunoglobulin superfamily consist of proteins that contain 
immunoglobulin structural repeats such as intercellular cell adhesion molecule-1 (ICAM-1), 
vascular cell adhesion molecule-1 (VCAM-1), and cadherins. T-cell adhesion to the antigen-
presenting cell (APC) is mediated by the interaction between LFA-1 on T cell and ICAM-1 
on APC. Similarly, T-cell adhesion to vascular endothelial cells can be mediated by 
interaction between very late antigen-4 (VLA-4) integrin receptor on T-cells and VCAM-1 
on vascular endothelial cells. Immune cells can extravasate from the blood to tissue through 
vascular endothelium after their firm adhesion on the surface of endothelial cells mediated 
by ICAM-1/LFA-1 and VLA-4/VCAM-1 interactions. Prior to firm adhesion of leukocytes 
(e.g., T cells) onto vascular endothelium, the rolling of these immune cells on the surface of 
vascular endothelium is mediated by the interaction of selectin on immune cells and Sialiyl-
Lewis-X molecules on the cell surface vascular endothelium. The structure of the 
extracellular domain of E-, L-, or P-Selectin has a lectin domain, an epidermal growth factor 
(EGF) domain, and two complement regulatory (CR) domains.
Cadherins (i.e., E-, P-, and N-cadherins) are cell surface calcium-binding glycoproteins with 
immunoglobulin repeats that interact in a homophilic manner to induce cell-cell adhesion in 
the intercellular junctions of biological barriers (i.e., intestinal mucosa barrier and the blood-
brain barriers). However, cadherins have also been shown to interact with integrin to mediate 
cell-cell adhesion. Finally, the extracellular matrix (ECM) proteins interact with integrins for 
anchoring cells to tissues as well as during tumor metastasis; ECM family includes 
fibronectin, vitronectin, fibrinogen, collagen, von Willbrand Factor, and laminin.
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Several cell surface cell adhesion receptors have been shown to internalize their ligands into 
the cytoplasmic domain of cells. LFA-1 receptors on T cells and HL-60 leukemic cells 
internalize cIBR peptide derived from the ICAM-1 protein [18–20]. In a similar fashion, 
ICAM-1 proteins on the surface of vascular endothelial cell mediate the uptake of cLABL 
peptide derived from the I-domain of LFA-1 protein [21]. RGD peptides that are specifically 
bound to highly expressed αVβ3 and αVβ5 integrins on cancer cells have been used as 
peptide-drug conjugates to selectively deliver drugs and nanoparticles to cancer cells over 
normal cells [5–10, 22]. Thus, many cell adhesion molecules have been conjugated to drugs 
and imaging agents for disease treatment and diagnostics.
This review is focused on the use of cell adhesion peptides to target therapeutic, antigenic, 
and diagnostic molecules to cancer and immune cells with upregulated or activated cell 
adhesion receptors. RGD peptides have been used to deliver anticancer drugs or diagnostic 
agents to cancer cells with upregulated integrins such as αVβ3 and αVβ5 integrins. ICAM-1 
peptides have been designed to target molecules to LFA-1 on the surface of immune cells 
and LFA-1 peptides to target ICAM-1 in epithelial and endothelial cells as well as immune 
cells. ICAM-1 peptides (i.e., cIBR) have been used to deliver an anticancer drug into cancer 
cells and an anti-inflammatory agent to suppress T-cell activation in rheumatoid arthritis 
(RA) animal model. LFA-1 peptides have also been used to deliver antigenic peptides to 
control immune responses in animal models of autoimmune diseases (i.e., RA, T1D, and 
MS). Cell adhesion peptides have been used to direct polymers and nanoparticles to deliver 
drugs and antigens to target cells. Although most conjugates of cell adhesion peptides have 
not yet reached clinical trials, the hope is that this review will stimulate interest in this area 
of research and provide background for investigating the potential of using other cell 
adhesion peptides for conjugates to deliver drugs and diagnostic agents.
B. Cell Adhesion Peptides
B.1. RGD Peptides Derived from ECM Proteins
Among the currently published in literature, one of the most well-studied cell adhesion 
peptides is RGD. The “Arg-Gly-Asp” or “RGD” sequence is found in many extracellular 
matrix (ECM) proteins, including fibronectin, vitronectin, fibrinogen, von Willebrand 
Factor, laminin, and collagen [12–15]. The RGD sequence is recognized by various integrin 
receptors on the cell surface for cell adhesion to ECM. The conformation of RGD sequence 
and the flanking residue have an important role in their recognition by specific receptor(s) in 
the integrin receptor family [29–30]. A cyclic RGD peptide, Integrilin®, has been used to 
clinically treat thrombosis because it inhibits platelet aggregation [31]. In this case, the RGD 
peptide binds to the integrin gpIIb/IIIa receptor on platelets and renders it unable to bind to 
fibrinogen for mediating platelet aggregation. Other cyclic RGD peptides have been 
designed for cancer treatment by inhibiting angiogenesis. These cyclic peptides selectively 
bind to αVβ3 and αVβ5 integrins, which are upregulated in tumors during angiogenesis [5, 
29].
The recognition and selectivity of RGD peptides are governed by the distance among the 
positively charged guanidinium cation of the Arg residue, the carboxylic acid anion of the 
Asp residue, and the hydrophobicity of the flanking residue (Table 1) [32–33]. Therefore, 
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the peptide conformation becomes essential in imposing the structure favorable for 
selectivity toward a specific target integrin. The formation of a cyclic peptide delivers a 
degree of backbone rigidity, which limits possible conformations to those favorable for a 
selected integrin. Integrilin® is a cyclic peptide that is formed by a disulfide bond from two 
cysteine residues at the respective N- and C-terminus. Its selectivity for gpIIb/IIIa integrin 
receptor is due to the restricted backbone conformation [31]. In contrast, cyclic cRGDfV and 
cRGDyV peptides use N- to C-terminus cyclization for a rigid backbone. They are selective 
toward αVβ3 and αVβ5 integrins and can be delivered to solid tumor to suppress 
angiogenesis [10, 30, 34–36].
B.2. Non-RGD Peptide
Recently, a new non-RGD cyclic peptide called ALOS4 (cyclo-(CSSAGSLFC)) was found 
to bind to overexpressed integrin αVβ3 in malignant melanoma cells (Figure 1; Table 1) 
[37]. ALOS4 peptide has been similarly explored as a tumor targeting peptide due to its 
binding affinity for αVβ3 integrin. The binding site for ALOS4 on αVβ3 integrin is different 
from the binding site of RGD peptide [37]. However, this peptide can be used as an 
alternative method of delivering cytotoxic drug to cancer cells overexpressing αVβ3 integrin.
B.3. LFA-1 Derived Peptides
Another group of cell adhesion peptides found in the literature have their origins in 
immunological processes, particularly in the inflammatory response. The immune system 
defends the body against foreign antigens via the involvement of T cells and antigen-
presenting cells. Interactions between ICAM-1 on the surface of APC and LFA-1 on T-cells 
are important not only for APC-T-cell adhesion but also as a co-stimulatory signal (Signal-2) 
for T-cell activation and proliferation. The antigen-specific activation of T-cells is also 
mediated by the T-cell receptor (TCR) recognition of antigen-major histocompatibility 
complex II (Ag-MHC II) presented by APCs. The TCR/Ag-MHC-II interactions can be 
categorized as signal-1, and the combination of signal-1 and -2 to form immunological 
synapse (IS) on the interface of T-cells and APC is necessary for T-cell activation and 
proliferation [38–40].
Inhibition of ICAM-1/LFA-1 interaction using monoclonal antibodies (mAbs) has been 
shown to suppress autoimmune diseases. Injections of a combination of anti-ICAM-1 and 
anti-CD11a mAbs twice a week for four weeks can induce immunotolerance to suppress 
type-1 diabetes and infiltration of islets by mononuclear cells in non-obese diabetes (NOD) 
mice [41]. A combination of these antibodies also prevents alograph rejection in cardiac 
transplantation in mice [42]. Anti-CD11a mAb (Efalizumab, Raptiva®) was previously used 
to treat psoriasis and it was also evaluated in phase I/II clinical trial for renal transplantation 
[43]. Unfortunately, this drug was pulled from the market because patients treated with this 
antibody developed progressive multifocal leukoencephalopathy (PML) [44]. Anti-ICAM-1 
(Enlimomab) was also investigated for the treatment of rheumatoid arthritis (RA) [45–46].
X-ray crystallography of the interactions between ICAM-1 heterodimer and the I-domain 
was shown in Figure 2A. Two D1 domains of ICAM-1 form a homodimer, and each D1 
domain binds to the I-domain of LFA-1. This interaction involves the metal ion dependent 
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adhesion site (MIDAS) region of I-domain. LFA-1 peptides (i.e., LABL or cLABL) were 
derived from the I-domain of LFA-1 α-subunit where their sequence is located in the 
interface region of binding between I-domain and D1 of ICAM-1 (Figure 2B). Linear LABL 
and/or cLABL have been shown to inhibit ICAM-1/LFA-1-mediated homotypic T-cell 
adhesion [47–48] as well as heterotypic T-cell adhesion to Caco-2 epithelial cell monolayer 
[49–51]. cLABL can also inhibit binding of the anti-ICAM-1 antibody to ICAM-1 on 
Molt-3 T-cells, suggesting that it binds to ICAM-1. Fluorescence-labeled cLABL peptide is 
also internalized by ICAM-1 into Molt-3 T-cells and Caco-2 cell monolayers, indicating that 
it has a potential for targeting drugs to ICAM-1-expressing cells [21]. Although LABL 
peptide was designed using information from residue mutation studies of the I-domain prior 
to the availability of the X-ray structure of I-domain/ICAM-1 complex, it is interesting to 
find that the sequence of LABL is located within the MIDAS region of the I-domain, and at 
the binding interface with ICAM-1 [52]. This correlation is one of many examples affirming 
the value of structural elucidations of protein-protein interactions in designing promising 
peptides of interest.
B.4. ICAM-1 Derived Peptide
Several linear and cyclic peptides designed from the sequences of the D1 of ICAM-1 can 
inhibit ICAM-1/LFA-1-mediated T-cell adhesion. Both IE and IB peptides were derived 
from D1 of ICAM-1. Analysis of the crystal structure of the ICAM-1/I-domain complex 
shows that the IE peptide epitope resides in the interface between D1 of ICAM-1 and the 
MIDAS region of I-domain of LFA-1 (Figure 2C). In contrast, epitope for the IB peptide 
was found in the interface of ICAM-1/ICAM-1 homodimer (Figure 2D). The IE peptide and 
its cyclic peptide derivatives (i.e., cIEL, cIEC, and cIER) were observed to enhance binding 
of anti-CD11a mAb binding to LFA-1 on T-cells, while they inhibit ICAM-1/LFA-1 T-cell 
adhesion. In contrast, IB peptide and its cyclic derivatives (i.e., cIBL, cIBC, and cIBR) block 
the binding of anti-CD11a mAb to LFA-1 and also inhibit ICAM-1/LFA-1-mediated T-cell 
adhesion [47–48, 53]. FITC-labeled cIBR peptide has been shown to colocalize with 
antibody to the β-subunit (R15.7 mAb) of LFA-1 on SKW-3 T-cells, which is detected with 
R-phycoerythrin (PE)-labeled goat antimouse secondary antibody, suggesting that cIBR 
binds to LFA-1 [18]. However, X-ray crystal structure of the I-domain/ICAM-1 complex 
showed that the cIBR sequence was at the homodimer region of ICAM-1 not at the interface 
of I-domain/ICAM-1. cIBR peptide inhibits binding of various mAbs to the MIDAS and 
IDAS regions of the I-domain [53]. NMR binding studies between cIBR peptide and I-
domain indicate that cIBR peptide binds to the IDAS region of the I-domain [54]. Thus, the 
hypothesis is that binding of cIBR to the IDAS region of I-domain induces the 
conformational change, which inhibits I-domain binding to ICAM-1 and to anti-I-domain 
mAbs.
C. General Principle of Peptide-Drug Conjugates (PDC)
Peptide-drug conjugates (PDC) have been developed to target drugs and radioisotopes to 
specific cells for therapeutic and diagnostic purposes [4, 23]. This method is similar to 
antibody-drug conjugates (ADC), which have been successfully used to treat cancer [24–
27]. For example, Kadcycla® and Adcetris® are antibody-drug conjugates on the market that 
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are currently used for treating cancer patients [27]. The underlying principle is to utilize the 
specific binding property of the targeting peptide to unusually upregulated receptors on the 
surface of diseased cells compared to normal cells. This would render the concentration of 
the delivered drug to be higher in diseased cells than in normal cells. The ultimate aim for 
PDC is to be selective for diseased cells, consequently lowering the occurrence of drug side-
effects with the conjugates, compared with the sole parent drugs in patients.
PDC has three fundamental components: 1) the targeting peptide, 2) the linker, and 3) the 
“drug payload” [23, 28]. The peptide has a function to direct the drug to a specific type of 
cell. It is often that the peptide segment of the PDC binds to the target receptor on the cell 
surface followed by PDC internalization into intracellular space via receptor-mediated 
endocytosis. The PDC enters the early endosomes, then moves to late endosomes and, 
finally, to lysosomes. The peptide portion on the PDC is degraded in the lysosomes, 
consequently releasing the drug intracellularly to exert its activity. The linker between 
peptide and drug can be designed as either fixed or cleavable to control the drug release 
kinetics at the desired site (i.e., target cells or tissue). The release of the drug payload from 
the linker can be accomplished enzymatically or via a change in pH inherent to the cellular 
compartments in intracellular spaces of targeted cells. However, the linker has to be 
sufficiently stable in the systemic circulation and easily cleaved only when the PDC reaches 
the target cells; thus, the drug should not be prematurely released from the PDC prior to 
reaching its target cell or tissue.
D. Cell Adhesion Peptide-Drug Conjugates (PDC)
D.1. RGD-Drug Conjugates for Therapy
Many cytotoxic anti-cancer agents remain unviable for widespread clinical use because of 
harmful side effects resulting from their non-selective delivery between normal and cancer 
cells. One good example is paclitaxel (PTX), which is an effective cytotoxic anti-cancer drug 
that targets microtubule formation inside cancer cells [55]. As earlier described, one of the 
hallmarks of angiogenesis in tumors is the overexpression of the αVβ3 integrin, to which 
certain RGD peptides selectively bind over other integrins on normal cells [8, 29, 34]. PTX 
was then conjugated to RGD peptide in an intent to enhance its targeting to tumor cells and 
to overcome some of its drawbacks such as low solubility and systemic toxicity [55]. In this 
case, PTX was conjugated to bivalent and tetravalent RGD-based integrin ligands. While 
most RGD constructs employed in literature resemble the RGDfK construct of Cilengitide 
(Table 1), this study utilized a unique cyclic RGD pentapeptide construct, which 
incorporated 1-aza-1-bicycloalkane amino acids (Figure 3) [10, 55]. Single and multiple 
units of cyclic RGD were conjugated to the PTX payload via a triazole ring linkage, which 
were subsequently connected to ethylene glycol units by an amide function (Figure 3A) 
[55]. Mono-, bi-, tetravalent conjugates of RGD-PTX conjugates have been shown to inhibit 
binding of vitronectin to αVβ3 integrin receptor with relative inhibitory activities observed 
to be highest with tetravalent > bivalent > monovalent RGD-constructs [55]. The bivalent 
RGD-PTX showed cell selectivity toward IGROV-1 and IGROV-1/Pt1 ovarian cells, 
compared with the other conjugates. Bivalent RGD-PTX also showed a similar activity as 
PTX in suppressing tumor growth of xenografted IGROV-1/Pt1 tumor.
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In order to similarly improve their therapeutic index by enhancing targeted delivery to tumor 
cells, both camptothecin (CPT) and chlorambucil (CLB) were conjugated to RGDfK using a 
bi-forked linker (Figure 3B) [56]. The overall intent was to create an RGD-targeted “double-
drug attack”, which would both be more potent and less likely to allow the tumor to develop 
any adequate drug resistance [56]. CPT is a very potent inhibitor of topoisomerase I enzyme; 
unfortunately, CPT has off-target cytotoxicity and poor solubility [56]. On the other hand, 
CLB is a DNA alkylator and an established anti-leukemic drug. In vitro, CLB was observed 
to be relatively inactive in its free form against melanoma and non-small cell lung cancer 
cell lines. However, conjugation of CLB to the carrier peptide via an amide- or ester-bonded 
linker with the lysine residue of RGDfK recovered its “activity” against murine leukemic 
cells [56]. Unlike the multimeric RGD construct, the enhanced cytotoxicity of this dual-drug 
conjugate was achieved through modifications of the payload component. Variations in the 
drug linkages were designed to achieve a sequential release of the drug upon reaching its 
target as directed by the RGD component. Relative stabilities of the varied drug-linked 
constructs were assessed across different pHs (ranging from physiologic to acidic) in order 
to survey their drug release profiles in the simulated environments of their tumor targets. 
Further bio-stability evaluations of these constructs were done in murine liver homogenate, 
confirming that although all constructs degraded, only conjugates with the carbamate and 
ester drug-linked functionalities showed the release of the free drug. This is in contrast to the 
construct with the amide-linked payload, which decomposes within minutes in the 
enzymatic environment without releasing the free drug.
Relative cytotoxicities of the mono and dual drug conjugates were evaluated against free-
CLB/CPT in vitro using αVβ3-overexpressing B16F10 (human non-small cell lung 
carcinoma), H1299 (murine melanoma), and αVβ3-negative HEK (human embryonic 
kidney) cell-lines. In vitro growth inhibition assays revealed that bi-loaded CPT conjugate 
was more potent than mono-loaded counterparts and free-CPT. Furthermore, although 
growth inhibition data also showed that mixtures of free-CLB/CPT mixtures were cytotoxic 
in all cell lines, the dual-drug RGD construct showed the greatest cytotoxicities against 
αVβ3 overexpressing cell-lines (i.e., human non-small cell lung carcinoma and murine 
melanoma) than mono-drug conjugates and mixtures of free-CPT/CLB. Even more 
remarkable are the differences in cytotoxicity when ratios between “targeted” to “off-target” 
IC50s are compared, thus showing the potential of the RGD-construct in reducing off-target 
(i.e., non-αVβ3 overexpressing cell) toxicities in next-generation CPT and CLB therapies.
W22 PDC is a conjugate between cyclo(RGDyK) and PD0325901, using a PEG-succinate 
linker. W22 is aimed at treating glioblastoma in the central nervous system (CNS) (Figure 
3C) [57]. PD0325901 is a potent inhibitor of mitogen-activated protein kinase-1/2 (MEK1/2) 
– an important signaling key player during receptor tyrosine kinase (RTK) activation via 
extracellular signal-regulated kinase (ERK) pathway. Because RTK is upregulated in 
glioblastoma, inhibition of MEK1/2 activity suppresses RTK activation to inhibit 
glioblastoma growth. Unfortunately, intracellular delivery of PD0325901 is not efficient. 
Thus, W22 PDC was designed to improve targeting and drug-uptake to glioblastoma. The 
drug is released via cleavage of the ester bond between PD0325901 and the linker [57]. In 
vitro, the W22 PDC was more active in αVβ3 expressing U87MG cancer cells than A549 
control cells. It has a higher efficacy than PD0325901 alone in U87MG and U251MG cells, 
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which are cell lines derived from glioblastoma. The glioblastoma tumor suppression in vivo 
was observed to be slightly better when the animals were treated with W22 PDC compared 
with controls PD0325901 or RGD-PEG+PD0325901. It was confirmed that the W22’s 
mechanism of action is via suppression of the pERK1/2 expression. Furthermore, results 
indicate that the RGD peptide can improve the selectivity and uptake of PD0325901 in 
glioblastoma cells in vitro and in vivo.
A novel “photolabile switch” has been incorporated into the cRGDfK peptide component of 
a PDC (Figure 3D). In this construct, the lysine residue is conjugated via an amide bond to a 
ruthenocene complex, which serves as the payload toxic drug (component). In addition, the 
Asp residue of the RGD sequence is derivatized with a dicyanocoumarin protecting group 
(DEAdcCE) via an ester bond – resulting in a photo cleavable “cage” for the RGD 
component [58]. Due to the protection of the Asp residue, this RGD peptide will not be 
recognized by the target integrin receptor. Thus, the activity of this PDC is initiated by the 
cleavage of the ester bond between the Asp residue and the photosensitive DEAdcCE 
moiety. After the release of DEAdcCE moiety using a biologically compatible green light, 
the RGD sequence will be active for integrin recognition and will accordingly deliver the 
payload to its intended cancer target. Because the required “activating” green light has a 
much longer wavelength than UV wavelengths, it offers a safer alternative to previously 
reported photolytic constructs requiring UV light [58]. Furthermore, a methyl group near the 
cleavable ester bond between the caging group and the RGD-Drug construct has been 
reported to provide a vital structural feature that minimizes the unfavorable aspartimide 
forming side-reaction in its synthesis [58]. This methyl group perhaps may even contribute 
to the increased stability of this ester bond in physiological conditions, where the construct 
has not yet been reported to be tested [58]. Nonetheless, an RGD-based prodrug that is 
photoactivated by a biologically compatible green light presents a safe and novel addition to 
the growing examples of cell-adhesion peptide-based drug delivery.
D.2. RGD Peptide Conjugates for Diagnostics
Because of the ongoing success of RGD peptide conjugates in targeting drugs, the RGD 
conjugates have also been designed as diagnostic agents to localize cancer cells within the 
tissue. RGD peptides can be labeled with radioisotopes, near IR (NIR) dyes, and magnetic 
resonance imaging (MRI) contrast agents. As an example, cyclic RGDfK was linked to a 
fusion of human serum albumin and tissue inhibitor of metalloproteinase 2 (HSA-TIMP2) to 
make RGD-HSA-TIMP2 (Figure 3E) [59]. 68Ga-NOTA- and 123I-radiolabeled were 
incorporated to RGD-HSA-TIMP2 for cancer diagnostics that can be observed by positron 
emission tomography (PET) and single photon emission computed tomography (SPECT). In 
vitro, RGD-HSA-TIMP2 was engulfed more efficiently (91%) than HSA-TIMP2 (45%) by 
U87MG cancer cells due to the recognition of the RGD peptide [59]. RGD-HSA-TIMP2 
also suppressed the proliferation of U87MG cancer cells better than HSA-TIMP2. Uptake of 
68Ga-NOTA-RGD-HSA-TIMP2 is higher in U87MG cells than in C6 cells, and its uptake by 
U87MG cells can be inhibited by free RGD peptide in solution. This suggests that the 
uptake of the conjugate is mediated by the recognition of RGD peptide by αVβ3 integrins on 
U87MG cancer cells. The uptake of 123I-RGD-HSA-TIMP2 was reported to be higher than 
123I-HSA-TIMP2 by xenografts of human glioma cancer cells in nude mice, as detected by 
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SPECT; however, the images were not of good quality [59]. On the other hand, PET showed 
a good quality image of tumor xenograft using 68Ga-NOTA-RGD-HSA-TIMP2, with no 
68Ga-NOTA-HSA-TIMP2 image detected in the tumor.
In rheumatoid arthritis (RA), angiogenesis to increase vascularization was observed in the 
synovium along with the increase in the expression of αVβ3 integrins [60]. Thus,99mTc 
(HYNIC-3PRGD2)(tricine) called TPPTS is a cyclic RGD peptide dimer with radioisotope 
99mTc. TPPTS has been utilized to detect the upregulation of αVβ3 integrins in endothelium 
during inflammation in RA using the SPECT system [60]. In this study, adjuvant induced 
RA in Sprague–Dawley rat was used as an animal model. After 30 min of TPPTS injection, 
the compound was observed around the rat arthritic ankles. This agent was also observed in 
various other organs, including bladder, kidneys, and liver. There was a linear correlation 
between the expression of αVβ3 integrin and the deposition of TPPTS in the arthritic ankles 
[60]. Furthermore, the amount of TPPTS was significantly higher in the arthritic ankles than 
untargeted control imaging agents with no RGD peptide. These results indicate that the high 
TPPTS deposition is due to binding of RGD peptide to upregulated αVβ3 integrin and has 
potential use as a diagnostic agent for RA
D.3. Non-RGD Peptide Conjugates
Recently, ALOS4 has been discovered as a new non-RGD cyclic peptide 
[Cyclo1,9(CSSAGSLFC)] that also binds to the αVβ3 integrin receptor. ALOS4 was 
conjugated to fluorescein isothiocyanate (FITC) via a γ-aminobutyric acid (GABA) linker, 
to make FITC-GABA-ALOS4 [37]. This molecule was engulfed by WM-266-4 melanoma 
cells via binding to upregulated αVβ3 integrins, as detected by FACScan [37]. The high 
deposition of FITC-GABA-ALOS4 was found at the tumor xenograft of WM-266-4 
melanoma cells in nude mice, indicating tumor targeting by ALOS4 peptide. The peptide 
was then conjugated to camptothecin (CPT) to make CPT-GABA-ALOS4, and the 
cytotoxicity of CPT-GABA-ALOS4 was evaluated in WM-266-4 metastatic melanoma cells 
and non-malignant human kidney HEK-293 cells. The results showed that CPT-GABA-
ALOS4 killed WM-266-4 cells in a dose-dependent manner to as much as 70% at 10 μM. In 
contrast, it only killed 30% of non-malignant HEK-293 with the same dose [37]. Because 
non-malignant HEK-293 do not overexpress αVβ3 integrin on their cell surfaces, the results 
suggest that selectivity of ALOS constructs for WM-266-4 over HEK-293 cells are due to 
the overexpression of αVβ3 integrins on WM-266-4 cells.
CPT-GABA-ALOS4 also shows a remarkable contrast in cancer-specific cytotoxicity 
compared with free CPT and two other cytotoxic drugs. In addition, the free CPT and two 
other cytotoxic drugs consistently killed considerable percentages of cell-populations in both 
WM-266-4 and non-malignant HEK-293. This study presents a promising non-RGD 
targeting peptide for the enhancement of chemo-stability and effective tumor-specific 
delivery of cytotoxic drugs [37].
D.4. ICAM-1 Peptide Conjugates
In the context of the immune response, cIBR peptide was derived from the sequence of 
ICAM-1. FITC-labeled cIBR has been shown to bind and be internalized by LFA-1 on the 
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surface of T-cells [18, 53]. Antibody inhibition and colocalization studies indicate that cIBR 
peptide binds to the I-domain of LFA-1 [53]. An NMR study shows that cIBR peptide binds 
at the IDAS region of the I-domain [54]. Conjugation of cIBR with methotrexate (MTX) to 
form MTX-cIBR has been shown to suppress rheumatoid arthritis in rat adjuvant arthritis 
model. In this case, conjugation to the cell adhesion/targeting peptide - cIBR lowered the 
toxicity of MTX [61].
D.5. Bifunctional Peptide Inhibitors (BPI)
Similar to the targeting design of RGD-conjugates, Bifunctional Peptide inhibitors (BPIs) 
are conjugates of an antigenic and cell adhesion peptide. They were designed to selectively 
alter the immune cell phenotypes from inflammatory to regulatory or suppressor cells in an 
antigenic-specific manner [62–63]. It is hypothesized that if BPIs suppress only a 
subpopulation of immune cells in an antigenic-specific manner, then BPIs can be an 
alternative solution to current drugs for autoimmune diseases, which normally suppress the 
general immune response. Suppression of the general immune response increases the risk for 
patients to be unable to fight pathogenic infections. For example, Tysabri® (Natalizumab) 
was withdrawn from the market because several treated patients developed progressive 
multifocal leukoencephalopathy (PML), most likely because of its suppressive effects on the 
general immune response rather than those associated only with the autoimmune disease 
[64–66]. Later, the use of Tysabri® was reinstated after providing certain precautions of its 
uses [67].
BPI molecule is a conjugate between a cell adhesion peptide (i.e., LABL) and an antigenic 
peptide specific for controlling a specific subpopulation T-helper (Th) cells that recognize 
the antigen [68–70]. The design of BPI is aimed at interfering with the formation of the 
immunological synapse (IS) during the T-cell activation and differentiation, when the T-cells 
bind to APC with a specific antigen-major histocompatibility complex-II (Ag-MHC-II) 
presentation (Figure 4A) [62–63]. It has been shown that the interaction between T-cell and 
APC forms IS on their interface, which resembles a “bull’s eye” structure [38–40]. IS is a 
cluster of Ag-MHC-II/TCR complexes (Signal-1) in the center, and a cluster of ICAM-1/
LFA-1 complexes in the outer ring of the “bull’s eye”. Before the final IS is formed at the 
initial contact of T cell to APC, signal-2 complexes are in the center ring and the signal-1 
complexes are in the outer ring to form an initial “bull’s eye”. Consequently, the two clusters 
of signals translocate or “trade places”, where the signal-2 complexes migrate to the outer 
ring, and the signal-1 complexes move to the center to form an inverted bull’s eye, which 
ultimately signals the inflammatory response. It was proposed that disrupting this final bull’s 
eye would trigger the proliferation of specific Th cells that recognize specific antigen on the 
MHC-II, resulting in antigen-specific tolerance and immunosuppression.
It has also been shown that delivery of soluble antigenic peptide can induce immune-
tolerance in the animal models of autoimmune diseases such as multiple sclerosis (MS), 
rheumatoid arthritis (RA), and Type-1 diabetes (T1D) [71–75]. It is proposed that the 
soluble antigenic peptide binds to immature dendritic cells (DCs) that lack CD80 and/or 
CD86 molecules. Therefore, the presence of MHC-II/Ag on immature DCs without any co-
stimulatory signal from CD80 and/or CD86 renders naïve T-cell/DC interactions result in the 
Moral and Siahaan Page 10













differentiation of naïve T-cells to produce regulatory T-cells (Treg) [76]. Tregs produce 
regulatory cytokines to suppress the activation of the inflammatory T-cells such as Th1 and 
Th17 and suppresses the autoimmune disease progression.
BPI molecules were designed to simultaneously bind to empty MHC-II and ICAM-1 on the 
surface of APC and block the formation of the IS when incoming T-cells bind to APCs 
labeled with BPI (Figure 4B). To accommodate BPI’s simultaneous binding to MHC-II and 
ICAM-1, both antigenic and LABL peptides were docked to the X-ray structures of MHC-II 
and ICAM-1, respectively, as if these two proteins sit on the cell surface [74]. The length of 
the linker between the antigenic peptide and LABL peptide was measured by measuring the 
distance between the N-terminus and LABL peptide and the C-terminus of the antigenic 
peptide. The linker was initially generated by a combination of aminocaproic and glycine 
amino acids to accommodate simultaneous binding of both peptides to the respective target 
receptors. The concept of BPI was evaluated in animal models of autoimmune diseases, 
including T1D, MS, and RA.
D.5.1. BPI for Multiple Sclerosis—MS is an autoimmune neurodegenerative disease in 
which the immune cells infiltrate the central nervous systems (CNS) and degrade the myelin 
sheath of neuronal axons. The myelin sheath is partly composed of proteolipid proteins 
(PLP), myelin basic proteins (MBP), and myelin oligodendrocyte glycoproteins (MOG). 
During the disease progression, a subpopulation of T-cells recognize peptides from PLP, 
MBP, and MOG proteins as antigens. BPI has been developed as a potential treatment for 
MS. To evaluate the activity of BPI molecules as potential therapeutics for MS, experimental 
autoimmune encephalomyelitis (EAE) animal models have been extensively used as models 
for MS [63, 68–70]. EAE models show symptoms and neurodegeneration similar to MS. 
Relapsing and remitting MS (RRMS) model and chronic progressive MS (CPMS) EAE 
animal models have been used to evaluate potential therapeutic agents for MS.
The RRMS EAE mouse model (female SJL/J mice) can be stimulated using PLP peptide in 
complete Freund’s adjuvant (CFA) on day 0, followed by injection of pertussis toxin on the 
same day and on day 2. Disease symptoms in mice start manifesting on day 9, with 
maximum disease exacerbation around days 13–15, followed by disease remission starting 
on day 20. The disease scores are low around days 30–45, reflecting disease remission. 
Animals show disease relapse again with high disease scores after day 45. At relapse, mice 
show high disease scores at day 54 and forward. PLP-BPI molecules have been shown to 
suppress the disease symptoms or lower the disease scores when injected on days 4, 7, and 
10 with 100 nmol/injection [69–70]. PLP-BPIs suppress disease exacerbation and prevent 
the onset of relapse in the RRMS EAE model as a prophylactic type of treatment. PLP-BPI 
has been shown to induce remission during disease exacerbation faster than the control when 
injected at the beginning of disease exacerbation on day 11, suggesting the molecule can be 
used to suppress the disease progression. Finally, injections of PLP-BPI on days −11, −8, −5 
as vaccine-like treatment before the stimulation of the disease on day 0 can also suppress the 
onset of EAE disease symptoms [80–82].
The CPMS EAE model (C57BL/6 mice) can be generated by injection of MOG peptide in 
CFA on day 0, followed by injections of pertussis toxin on the same day and on day 2. 
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Observable disease symptoms begin to manifest by day 7 and peak by day 13, with 
symptoms continuing at high scores without any remission. After induction of CPMS EAE 
in mice, MOG-BPI (100 nmol/injection) was administered on days 4, 7, and 10. Results 
showed continuous suppression of the disease scores until the end of the study on day 25 
[83]. Multivalent antigen BPIs were also designed with both PLP and MOG peptides 
attached to LABL peptide to form PLP-MOG-BPI [83]. When injected into CPMS EAE 
mice on days 4, 7, and 10 at 100 nmol/injection, this multipeptide conjugate suppressed the 
disease better than MOG-BPI and MOG peptide alone. This suggests that a combination of 
PLP and MOG antigens in BPI can suppress T-cells that recognize both PLP and MOG. It 
was suggested that, due to the severity of the CPMS model, immune cells in this model also 
respond to antigens from PLP in addition to antigens from MOG. This is normally described 
as antigenic spreading. Administrations of 100 nmol/injection of PLP-MOG-BPI in RRMS 
EAE mice on days 4, 7, and 10 also suppress the disease symptoms significantly better than 
control.[83] As expected, MOG-BPI did not suppress the RRMS EAE primarily because the 
disease was stimulated with the PLP peptide. This suggests that BPI molecules suppress 
EAE in an antigene-specific manner, with MOG sensitivity being a potential hallmark of a 
more advanced/latter stage of the disease model than PLP.
To elucidate BPI’s potential mechanisms of action, several experiments were carried out. 
These included evaluation of BPI’s effects on: (a) cytokine production, (b) axon 
demyelination, and (c) blood-brain barrier (BBB) leakiness. The effects of BPI- and PBS-
treatments on the inflammatory, regulatory, and suppressor cytokines were evaluated in EAE 
mice. BPI molecules significantly suppressed the productions of inflammatory cytokines 
IL-17, IL-6 and IFN-γ, compared with PBS controls [80, 82–83]. BPI-treated mice had a 
significantly higher production of regulatory (i.e., IL-2 and IL-10) and suppressor (i.e., IL-4 
and IL-5) cytokines compared with that of PBS-treated ones [68–69, 80, 82–83]. These 
suggest that BPI alters the balance of immune cells from predominantly inflammatory to 
regulatory and/or suppressor phenotypes. Upon evaluation of the axon demyelination in the 
brain, BPI-treated EAE mice had intact myelination of their brains, while the PBS-treated 
EAE mice had clear demyelination of the axon. This indicates that BPIs suppress the 
activation of immune cells and prevent the infiltration of immune cells into the CNS. Finally, 
MRI was used to detect the leakiness of the BBB through the administration and detection of 
MRI contrast agent – Gadopentetic acid (Gd-DTPA) – in the brain [82]. Three different 
groups of mice were administered with Gd-DTPA: (1) normal mice, (2) EAE mice, and (3) 
EAE mice treated with BPI. Normal mice showed very limited deposition of Gd-DTPA in 
the brain, while the non-treated EAE mice had significantly higher Gd-DTPA deposition in 
the brain, suggesting that the BBB of EAE mice are leaky [82]. It is interesting to find that 
the deposition of Gd-DTPA in the brains of BPI-treated EAE mice are very low or even 
similar to those in the normal mice. This indicates that BPI treatments prevent the leakiness 
of the BBB.
D.5.2. BPI for Rheumatoid Arthritis (RA)—BPI molecules (i.e., CII-BPI-1, -2, and -3) 
were also evaluated in collagen-induced arthritis (CIA) mouse model [73]. There were two 
CIA mouse models used in this study. The first model used DBA/1J mice, with the disease 
stimulated using bovine type II collagen in CFA on day 0, followed by a booster dose on day 
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21. Manifestation of arthritis disease symptoms (i.e., paw swelling, inflammation) began 
between days 24 and 27. CII-BPI molecules (i.e., CII-BPI-1, -2, and -3) and CII-1 peptide 
were administered on days 19, 22, and 25, at a dose of 100 nmol/injection. CII-1 peptide 
alone is an antigenic peptide that has been used previously to suppress RA in an animal 
model. MTX-cIBR conjugate has also been shown to suppress arthritis in rat adjuvant 
arthritis model, and in this case was used as a positive control. For the positive control 
group, MTX-cIBR was injected daily (5 mg/kg) for 10 days starting on day 19. Results 
showed that CII-BPI-1 significantly suppressed the increase in paw volumes compared with 
those treated with PBS [73]. CII-BPI-1 appeared to have been more potent than CII-1 
peptide alone, with three injections of CII-BPI-1 having a potency similar to 10 injections of 
MTX-cIBR. Next, CII-2 and CII-3 peptides alone were similarly compared to their 
respective BPI molecules (i.e., CII-BPI-2 and CII-BPI-3). CII-BPI-2 was found to be better 
than CII-2, CII-3, and CII-BPI-3. CII-BPI-3 had a better efficacy than CII-3 peptide alone 
[73].
The second CIA model used DBA1BO mice, which were stimulated with chicken collagen-
II on CFA emulsion on day 0, and a booster dose on day 21. Disease symptoms began to 
show on day 17, and treatment was carried out with BPI on days 17, 22, and 25 (3x), or on 
days 17, 22, 25, and 28 (4x) [73]. This study showed that CII-BPI-2 was more potent than 
CII-2 peptide during the administration of 3 doses of peptides. These confirmed that BPIs 
were more effective than their parent antigenic peptides. The histopathology study of the 
joints showed that both CII-BPI-2 and CII significantly suppress the damage and 
inflammation in the knee joints, compared with those treated with PBS. Compared with 
PBS, CII-BPI-2 suppressed productions of inflammatory cytokines IL-6, IL-17, IFN-γ, IL-2, 
and TNF-α while enhancing the regulatory cytokines IL-10.[73] These further indicate that 
BPI molecules alter the balance of immune cells from inflammatory to regulatory cells.
D.5.3. BPI for Type-1 Diabetes—Type-1 diabetes (T1D) is an autoimmune disease in 
which β-cells in the islets of the pancreas are destroyed by the immune cells, and the disease 
progress is signified by infiltration of the islets by T-cells. Previously, soluble GAD65208-217 
peptide derived from residues 208–217 of glutamic acid decarboxylase 65 (GAD65) can 
suppress type-1 diabetes in NOD mice [77–79]. Thus, conjugation of GAD65208-217 and 
LABL peptides via a linker (e.g., Acp-Gly-Acp-Gly-Acp) created the GAD-BPI conjugate 
[74]. The linker and its length were designed for simultaneous binding of BPI to MHC-II 
and ICAM-1 on the surface of APC, ultimately to block the formation of IS during the 
activation of T-cells.
The efficacy of GAD-BPI was evaluated in non-obese diabetic (NOD) mice, in which the 
disease was stimulated with the GAD65208–217 peptide in complete Freund’s adjuvant 
(CFA) on day 0 to developed T1D [74]. GAD-BPI was injected intravenously (i.v.) into 
NOD mice on days 0 and 7, and the mice were sacrificed on day 8 for evaluation of T-cell 
infiltration of islets called insulitis. For a control group, mice were injected with PBS. The 
islets of mice treated with GAD-BPI were 85% normal (or 15% insulitis), while those 
treated with PBS only had 30% normal (or 70% insulitis). This result indicates that GAD-
BPI suppressed the activation of T-cells to prevent insulitis. GAD-BPI induced the 
production of IL-4 producing cells.
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Next, T cells isolated from both GAD-BPI- and PBS-treated T1D NOD mice were isolated, 
and these two groups of T-cells were evaluated in NOD.Scid mice in co-adoptive transfer 
experiments [74]. Two groups of NOD.Scid mice were injected with immune cells isolated 
from the NOD mice that have developed T1D. Then, the two groups of NOD.Scid mice were 
injected with T-cells isolated from GAD-BPI-treated NOD and PBS-treated mice. NOD.Scid 
mice (77%) that received T-cells isolated from GAD-BPI-treated mice did not have diabetes, 
with glucose levels below 250 mg/dL. Only 19% of NOD.Scid mice that received T-cells 
isolated from PBS-treated mice did not get diabetes. These results suggest that GAD-BPI 
can suppress the insulitis in NOD and NOD.Scid mice by suppressing T-cell activation. The 
study also showed that the GAD-BPI can simultaneously bind to ICAM-1 and MHC-II on B 
cells isolated from NOD mice. The anti-MHC-II and anti-ICAM-1 mAbs co-capping studies 
on B cells, after treatment with GAD-BPI and unlinked GAD+LABL peptides, showed a 
high probability that GAD-BPI binds simultaneously to MHC-II and ICAM-1 on the surface 
of B cells [74]. This also suggests that GAD-BPI can inhibit the formation of the 
immunological synapse and suppress T-cell activation in autoimmune diseases.
E. Peptide-Particle and Peptide-Polymer Conjugates
Overall efficacies reported on BPIs and PDCs have inspired innovations which either aim to 
utilize their targeting abilities, or load higher number of active BPIs or PDCs in a single 
pharmacological construct such as polymers and nanoparticles. Nanoparticles have been 
used to deliver drugs to improve drug dosing and for controlled drug release. Many 
nanoparticles are being developed as cancer therapeutic and diagnostic agents. There are 
several approved drugs in nanoparticle formulations including Doxil [84–86], DepoCyt [87], 
and Estrasorb [88]. For example, Doxil is a liposome formulation of doxorubicin 
functionalized with PEG [84–86]. Some of these particles have been targeted to a particular 
type of cell or tissue.
E.1. RGD-conjugated Biopolymers and Nanoparticles
Biopolymers bearing RGD peptides have been designed for tissue engineering and 
regeneration because RGD peptides can be used for cell recruitment and adhesion, 
especially for building tissues in wound healing, reconstructive surgeries, and neuronal 
regeneration. To exert RGD activity for integrin recognition, it is necessary for the peptide to 
have a distance from the polymer surface to avoid steric hindrance during their recognition 
by a specific integrin. It was suggested that the RGD peptide should be distanced from the 
polymer surface around 11 to 46 Å, using a PEG spacer for optimal interactions with 
integrin receptors on the cell surface [9, 89].
RGDfK peptides have been conjugated to chitosan, PEG polylactic acid (PLA), and 
polyethyleneimines (PEI) for delivering anticancer drugs and DNA. RGD peptide 
conjugated with polylactic acid (PLA) polymer (RGD-ST-NH-PEG-PLA) has been shown to 
induce attachment of human osteoblasts to the polymer [90]. This cell attachment can be 
blocked by soluble RGD peptide. In contrast, immobilized Arg-Ala-Asp (RAD) peptide 
attached to the polymer (RAD-ST-NH-PEG-PLA) did not initiate the attachment of human 
osteoblasts [90]. Taken together, the data indicate that the cell attachment of human 
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osteoblast cells to the polymer is due to the recognition of RGD peptide by integrin 
receptors on the cell surface.
As mentioned previously, liposomes have been used to deliver drugs to tumor cells, 
including RGDfK peptide constructs conjugated to PEG-2000 distearoylphosphatidyl-
ethanolamine (DSPE), for incorporation into liposomes to target cancer cells. RGD and 
RAD peptides conjugated to polyethylene glycol (PEG) were incorporated into long-
circulating liposomes (LCL) to make RGD-LCL and RAD-LCL. RGD-LCL shows 
significant binding to human umbilical vein endothelial cells (HUVEC) compared with LCL 
and RAD-LCL as negative controls [91]. Furthermore, binding of RGD-LCL was inhibited 
by soluble RGD peptide but not RAD peptide, indicating that the RGD-LCL binding to 
HUVEC was mediated by RGD peptide. Then, RGD-LCL was labeled with fluorescence 
dye Rho-PE and injected into tumor-bearing mice. The Rho-PE–labeled RGD-LCL was 
bound to the tumor vasculature, as observed by intravital microscopy [91]. Finally, 
doxorubicin-loaded liposomes (i.e., LCL, RAD-LCL, RGD-LCL) were injected into mice 
bearing a C26 tumor. The results showed that Dox-RGD-LCL suppressed tumor growth 
more significantly than those treated with Dox-RAD-LCL and Dox-LCL, thus confirming 
the role of RGD peptide in directing liposomes to tumor cells [91].
RGD-PEG-liposomes have been developed to deliver dexamethasone phosphate to treat 
arthritis in adjuvant-induced arthritis in rats [92]. As earlier mentioned, upregulated αVβ3 
integrins have been shown in arthritic tissues; thus, a high localization of RGD-PEG-
liposomes was found in the inflamed skin of joints of lipopolysaccharide-induced 
rheumatoid arthritis rats [92]. RGD-PEG-liposomes carrying dexamethasone were more 
potent in suppressing RA than blank liposomes containing dexamethasone alone, indicating 
the capability of RGD peptide to target liposomes to arthritis tissues.
Carboplatin is an anticancer drug and, although it is widely used, these types of drugs are 
known to have low cellular uptake and to generate multi-drug resistance in cancer therapy. 
One way to overcome drug resistance is by formulating carboplatin in unimolecular 
nanoparticles with the idea that the targeted carboplatin can be released in a pH-sensitive 
manner [93]. In this case, a block copolymer poly(amidoamine)-b-poly(aspartic acid)-b-
poly(ethylene glycol) (PAMAM-PAsp-PEG) was used as a core nanoparticle with multiple 
linkable arms. cRGDfC peptide was one of the linked moieties used to target the 
nanoparticles to cancer cells [93]. The core arm was connected to poly-aspartic acid chains 
in order to coordinate carboplatin on the nanoparticle through two carboxylic acid side 
chains of the series of Asp residues [93]. Additional arms that extend from the PAMAM 
core were conjugated to fluorescent dye cyanin5 (Cy5) in order to follow cell or tissue 
deposition of the nanoparticles. The uptake of RGD-containing nanoparticles was 3–4 fold 
more than nanoparticles without RGD peptide in ovarian cancer-3 (OVCAR-3) cells, 
indicating the role of RGD peptide and overexpression of αVβ3 integrins in the targeted 
nanoparticle delivery [93]. Furthermore, nanoparticles were internalized into lysosomes of 
the cancer cells. The pH drop resulting from the inherently acidic environment of the 
cancerous lysosomes protonates the carboxylic side-chains of the carboplatin-complexed 
poly-Asp network and releases the cytotoxic payload to its target [93]. In vitro, the 
carboplatin is released up to 88% at pH 5.5, while it is only released up to 18% at pH 7.4 by 
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the 50-hour time point, showing that carboplatin can be released in a targeted and controlled 
way in lysosomes of cancer cells. The cytotoxicity assays showed that RGD-containing 
carboplatin nanoparticles significantly suppress the OVCAR-3 cell viability, compared with 
carboplatin nanoparticles without RGD peptide and carboplatin alone [93].
E.2. Particles with Bifunctional Peptides
Recently, bifunctional peptide-targeting has been explored to improve tumor targeting and 
apoptosis effects. Here, nanoparticles were decorated with encapsulated docetaxel (DOC). A 
combination of HAV, NGRRGD, and AVPIAQK sequences was implemented in HRK-19 
peptide (HAVRNGRRGDGGAVPIAQK) to target the DOC-bearing nanoparticles to tumor 
cells. The HAV, NGR, and RGD sequences were used to target cadherin, αVβ3 integrins, and 
aminopeptidase-N (CD13), respectively, on tumor blood vessels [94]. At 5 nM dose, the 
apoptotic index of DOC-loaded-HRK-19 peptide nanoparticles was significantly higher than 
DOC alone on treated A549 cancer cells. Nanoparticles decorated with HRK-19 peptide 
(DOC-loaded-HRK-19) penetrated xenograft tumor with high efficiency in vivo, with 
slightly better efficacy than that of drug alone, in extending animal survival [94]. The 
nanoparticle efficacy was significantly better than saline and HRK-19 alone in suppressing 
A549 tumor growth and extending animal survival [94]. DOC-loaded-HRK-19 nanoparticles 
also significantly suppressed pulmonary tumor metastasis of A549 cells, compared with 
saline and peptide alone.
E.3. LABL Conjugation to Particles for Delivery
CPP), has been conjugated to a linear LABL peptide to make the TAT-PEG-LABL conjugate 
[95]. The TAT peptide in the conjugate was complexed with luciferase DNA via electrostatic 
interactions by condensing them using calcium to form particles with a 300-nm size [95]. 
The LABL peptide had the role of targeting the particles to ICAM-1-bearing A549 cells for 
DNA internalization [95]. Upon activation of A549 lung epithelial cells with TNF-α, TAT-
PEG-LABL(DNA) enhanced luciferase transfection compared with TAT-PEG(DNA), 
suggesting that LABL peptide targets the particles into A549 cells [95]. The TAT-PEG-
LABL(DNA) transfection was also blocked by free LABL peptide and anti-ICAM-1 mAb, 
indicating that TAT-PEG-LABL(DNA) uptake was ICAM-1-mediated endocytosis via 
binding to LABL peptide on the surface of particles [95].
The surface of nanoparticles made from pluronic-F-127/PLGA was decorated with a cyclic, 
cLABL peptide (Cyclo-(1,12)-PenITDGEATDSGC) to produce cLABL-NP (or cLABL-
Pluronic-F-17-PLGA) [96]. The uptake of cLABL-NP was higher than that of NP (2.3 fold) 
alone by A549 lung epithelial cells bearing the ICAM-1 receptor. Internalized within 5 min, 
cLABL-NP had a fast kinetic uptake [96]. Uptake of cLABL-NP, however, was inhibited by 
cLABL and anti-ICAM-1 mAb, suggesting that the uptake was mediated by ICAM-1 
receptors on the cell surface [96]. It was suggested that the internalization of the cLABL-NP 
was induced by clustering of ICAM-1 to form multimeric interaction with the nanoparticles, 
similar to that of anti-ICAM-1 decorated nanoparticles [97–99]. The lysosome accumulation 
of cLABL-NP was within 1 h after incubation, compared with 2 h after incubation for blank 
nanoparticles. The cLABL-NP was removed from the lysosomes within 24 h and this 
removal was not due to a lysosomal disruption.
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Similar to BPI molecules, the development of soluble antigen arrays (SAgAs; Figure 5) was 
inspired by a combination of the BPI concept and Dintzis’ rules, which have been shown to 
induce immune stimulation or tolerance [100–106]. Dintzis’ rules indicated that induced 
immune responses are influenced by particle size, solubility, flexibility, antigen valency, 
spacing, and binding avidity. The BPI concept showed that a conjugation of an antigenic 
peptide and co-stimulatory signal peptide (inhibitor) can alter immune cell phenotypes [107–
108]. Thus, SAgAPLP-LABL molecules were designed to resemble BPI molecules containing 
a combination of PLP antigenic and LABL peptides linked to hyaluronic acid polymers with 
an 11:10 LABL:PLP peptide ratio per polymer unit (Figure 5) [103]. The SAgA molecules 
are soluble and small, with a size of <100kDa. The presence of multiple ligands on the 
polymer construct enhances avidity for dendritic cells. SAgAPLP-LABL delivers a 
multivalence of adhesion peptides, which have previously been reported to enhance cell-
binding by increased avidity and to inhibit inflammatory signaling by mimicking the native 
clustering of bound cell-surface protein targets related to the immunological synapse. 
Overall features of SAgAs fulfilled good tolerogenic properties according to Dintzis’ rules, 
and their efficacy was evaluated in the EAE animal model for MS. Compared with HAPLP, 
HALABL and HA alone (Figure 5), SAgAPLP-LABL had excellent efficacy in suppressing 
EAE in mice; however, administration of a 1:1 mixture of homopolymers HAPLP and 
HALABL also showed a significant disease suppression similar to that of SAgAPLP-LABL. 
These results support the idea that SAgAPLP-LABL is a novel and effective antigenic-SIT and 
affirm the need for co-delivering a cell-adhesion inhibitor and an antigenic peptide to induce 
degrees of immunotolerance in autoimmune diseases. Because comparable protections were 
delivered against murine EAE by administrations of the novel SAgAPLP-LABL, and a 1:1 
mixture of HAPLP+HALABL, the immunosuppressive mechanisms of both formulations 
remain uncertain; thus, further studies on their mechanism of action need to be explored.
In an attempt to elucidate the mechanism of action of SAgAs in vitro, a separate multi-
peptide construct using hyaluronic acid (HA) conjugated with multiple LABL and antigenic 
ovalbumin (OVA) peptides was synthesized to construct SAgAOVA-LABL [100]. The cellular 
binding and uptake properties of FITC-labeled SAgAOVA-LABL were compared to HAOVA 
and HALABL, using bone marrow derived dendritic cells (DC). The maturation of DC was 
accomplished using TNF-α. Because HA alone is a natural ligand to many cell surface 
receptors, observed fluorescence indicating substantial binding of unconjugated HA was 
expected [100]. SAgAOVA-LABL and HALABL both showed a considerable increase in 
binding to DCs compared with HA alone [100]. Because HAOVA did not appear to bind 
efficiently to DC, it is unclear if its grafting with LABL provided the slight binding 
enhancement in the SAgAOVA-LABL construct even though it has been suggested that 
antigenic peptides can bind with low affinity to empty MHCs of DC. As in the previous 
study, the degree of T-cell proliferation was determined after co-culture with groups of DC 
which were initially matured, primed and pre-treated with the different HA grafts. T-cell 
proliferation was measured by flow cytometry after 24-hours and 7-days. Both 
SAgAOVA-LABL and HALABL grafts showed a statistically significant reduction in cells 
which have divided vs. the untreated group and the negative control of T-cells alone. It was 
noted that there was no significant difference between the untreated control and cell group 
treated with HA alone.
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Because affecting T-cell proliferation can also correlate to a modified control in cytokine 
production, the production of TNF-α, IFN-γ, IL-4, IL-10, and IL-17 were investigated by 
ELISA [100]. HA and SAgAOVA-LABL did not show any increase in the levels of IFN-γ, 
IL-4, and IL-10. When compared with the untreated control, a significant reduction in TNF-
α and IL-17 secretion was observed in the presence of HA and SAgAOVA-LABL grafts. TNF-
α promotes inflammatory responses and can lead to various autoimmune and inflammatory 
diseases. IL-17 has likewise been associated with a wide range of similar diseases such as 
asthma, rheumatoid arthritis, psoriasis, and systemic sclerosis. Amounts of TNF-α in the 
medium of cells treated with HA, SAgAOVA-LABL and SAgALABL were from 10.9 ng/mL 
(untreated) to 3.7, 4.1, and 8.2 ng/mL, respectively. IL-17 produced from untreated cells was 
13.9 ng/mL, in contrast to those secreted by HA and SAgAOVA-LABL and SAgALABL-treated 
cells, which were below the detection limit of < 2 pg/mL. These are consistent with the 
significant reduction in T-cell-DC interactions observed in the presence of HA (79%), 
SAgALABL(82%), and SAgAOVA-LABL(85%), compared with the untreated control. These 
results demonstrate HA graft polymers as potential inhibitors of Th17 CD4 cell 
differentiation and unwanted inflammatory responses in the context of autoimmune diseases.
F. Conclusions
Cell adhesion peptides have been important innovations in addressing the problem of off-
target cytotoxicity and the side effects of drug molecules. Cell-adhesion peptides serve as 
effective targeting agents in directing diagnostic and therapeutic molecules toward diseased 
cells and tissues (e.g., cancer and autoimmune) often through abnormally overexpressed cell 
adhesion receptors. By mimicking native interactions of fully intact proteins, peptide 
epitopes derived from protein surfaces have been used to design targeting cell adhesion 
peptides. Insights on viable cell adhesion sequences have far evolved from the study of 
primary sequences and in vitro inhibition and/or binding studies to more direct 
crystallographic and structural techniques probing vital interactions of cell adhesion 
proteins. Current biophysical methods to visualize locations of viable cell-adhesion epitopes 
on intact protein structures facilitate the mining of vital amino acid sequences and a greater 
understanding of viable homing peptides for disease-specific delivery of drug and diagnostic 
molecules. Unlike intact proteins and antibodies, cell-adhesion peptides are simpler to 
synthesize, isolate, and manage. The absence of any tertiary structure renders them more 
forgiving in storage and formulation. More importantly, their considerably smaller size 
allows for multiple peptide units to be conjugated to a single construct for the enhancement 
of both potency and selective delivery of conjugated cytotoxic molecules. In promoting 
immunotolerance, BPI molecules deliver antigenic peptides to specifically suppress 
autoimmune diseases in animal models for type-1 diabetes, rheumatoid arthritis, and 
multiple sclerosis. They further demonstrate additional important roles of conjugate linkers, 
beyond the simple function of bridging targeting and payload components of a conjugate 
construct. From a pharmacokinetic standpoint, conjugates have to be stable in circulation 
until their target cells or tissues are reached, prior to the release of the drug. Thus, various 
factors need to be considered in designing conjugates for cell adhesion peptides, including 
the conjugation methods and the length of the covalent linker to control the stability and 
toxicity of the construct. In any case, the range of applications presented in the reviewed 
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conjugate molecules demonstrate good models to be adopted for next generation therapies to 
be considered for clinical trials.
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CIA collagen-induced arthritis
CLB chlorambucil
CNS central nervous systems








EAE experimental autoimmune encephalomyelitis
Moral and Siahaan Page 19














EGF epidermal growth factor




GAD65 glutamic acid decarboxylase 65
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ALOS4 Conjugates. ALOS4 peptide conjugated with either FITC or camptothecin using a 
GABA linker.
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X-ray structure of LFA-1 I-Domain in complex with ICAM-1 (PDB: 1MQ8). (A) ICAM-1 
protein forms a homodimer, which interacts with two separate I-domains of LFA-1 at each 
D-1 domain of ICAM-1. Counter-clockwise quarter-turn on the encircled interface shows 
(B) the interacting region of LFA-1 I-domain with ICAM-1, also referred to as the MIDAS 
region (yellow/gold), which overlaps with the region of the LABL peptide sequence (green). 
(C) Shows the region on LFA-1 interacting with the IEL sequence (purple) from ICAM-1. 
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(D) Maps regions on the ICAM-1 homodimer where IB (cyan) and IE (yellow) peptide 
sequences are located.
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RGD peptide drug conjugates. (A) RGD-PTX conjugates bearing: (i) monovalent, (ii) 
bivalent, and (iii) tetravalent RGD units; (B) Dual-Drug-RGD conjugates with camptothecin 
and/or chlorambucil; (C) W22-RGD conjugates using (i) PEG and (ii) amide linkers; (D) 
Photocontrolled RGD conjugate bearing a cleavable bond (green arrow) with a “caging” 
DEAdcCE group; and (E) RGD-HSA-TIMP2 conjugate, where cyclic RGDfK is linked to a 
fusion protein (HSA/TIMP2) through a thioether bond.
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Inhibition of intercellular Signal-1/Signal-2 surface protein interactions between antigen-
presenting (APC) and docked T-helper (Th) cells. Intercellular protein complexes cluster and 
translocate (A) to form the immunological synapse (IS), which precludes the triggering of 
inflammatory response processes. (B) Bifunctional peptide inhibitors (BPI), comprised of a 
covalently linked antigenic and Signal-2 inhibitor peptide (LABL), mimic interacting 
surfaces of both Signal-1 and -2 complexes, and preclude inflammatory responses by 
disrupting the protein clustering and translocation required in the IS, presumably due to the 
non-cleavable peptide linker.
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Derivatized hyaluronic acid (HA) polymers with multiple units of either conjugated 
antigenic or Signal-2 inhibiting peptides. Analogous to BPIs are Soluble Antigen Arrays 
(SAgAs), which are similarly derivatized HA polymers with multiple units of both antigenic 
and Signal-2 inhibitor peptides. Figure 1.
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Table 1
Peptide Names and Sequences
Name Peptide Sequence
RGD in Cilengitide Cyclo(RGDfK)
RGD Cyclo(RGDfV)
RGD Cyclo(RGDyV)
RGD in W22 PDC Cyclo(RGDyK)
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